Measles, mumps and rubella vaccine as an intralesional immunotherapy in treatment of warts

Shah, Aarti; Patel, Dhara; Vaaruni, Ravishankar

doi:10.18203/2320-6012.ijrms20160298

Cited by 11 publications

(18 citation statements)

References 15 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparable results were obtained by the study of Shah et al () in which complete response was reported in 72%, partial response in 16%, and no response in 12% of patients following intralesional MMR injection.…”

Section: Discussionsupporting

confidence: 65%

“…In MMR patients, we recorded mild to moderate pain during injection in 11 patients (55%), while it was recorded in 85.7% of patients by Nofal and Nofal (), 36% by Shah et al (), and 82.6% by Gamil et al ().…”

Section: Discussionmentioning

confidence: 71%

“…Treatment of warts is frustrating as ideal treatment with high effect and low recurrence has not been explored until now (Shah, Patel, & Ravishankar, ). Cryotherapy is a broadly used method for the treatment of warts with relative safety and moderate discomfort for patients (Campbell, ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: A randomized controlled trial

El‐Magiud

El‐Samea

Gaber

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Cutaneous warts are benign hyperkeratotic papillomas resulting from infection by human papillomavirus (HPV). Cryotherapy is a known method for warts treatment. Immunotherapy stimulates HPV recognition by the immune system; this helps resolution of warts. To determine the efficacy of intralesional immunotherapy with measles, mumps, and rubella (MMR) vaccine versus cryotherapy in the treatment of patients with multiple common and plantar warts. Forty‐eight patients with multiple common and plantar warts were divided into two groups: to undergo either intralesional injection of MMR vaccine (Group A), or cryotherapy (Group B). Forty patients completed the study. In the MMR group, 70% of the patients showed complete response, 5% partial response, and 25% showed no response to treatment. In the CRYO group, 45% of the patients showed complete response, 35% partial response, and 20% showed no response to treatment. The complete response was higher in the MMR group (70%) as compared to the CRYO group (45%), but the difference between the two groups was not statistically significant. Meanwhile, the partial response was significantly higher in the CRYO group. Intralesional MMR injection was a safe and effective treatment for multiple common and plantar warts as compared to cryotherapy.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: A randomized controlled trial

El‐Magiud

El‐Samea

Gaber

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…18 50 patients were injected with MMR vaccine out of which complete clearance was seen in 72%, 16% reported partial clearing and 12% of patients showed nil response in a 2016 done prospective study. 19 A comparison study with MMR vaccine group and another receiving Trichloroacetic acid (TCA) application topically was by Saveta et al again in 2016. MMR group 49.3% had higher than 75% improvement with 26.44% demonstrating complete resolution but TCA only had 11.11% showing more than 75% improvement with complete resolution in 7.94%.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of measles, mumps and rubella vaccine as immunotherapeutic agent for cutaneous viral warts

2020

View full text Add to dashboard Cite

Immunotherapy for management of cutaneous wart with measles, mumps and rubella vaccine (MMR) is a promising new modality of management. Evaluation of the same has been done by various studies over the years reporting its effectiveness. A literature search was done using PubMed and google scholar. This short narrative review documents the response rates in various clinical studies done till 2019 which have reported the efficacy of MMR vaccine as an immunotherapeutic agent which ranged from 26-84% graded as complete response which is complete clearance of the treated warts. These studies were performed for evaluating MMR vaccine as single agent or done in comparison with other therapeutic agents. The broad range of responses points to a need of doing further clinical studies which will substantiate the effectiveness of MMR vaccine in the treatment of cutaneous warts.

show abstract

“…However, there seems no consensus for a minimum dose of MMR vaccine, dosing frequency, and duration of therapy to treat warts. [ 8 9 10 13 14 15 16 17 18 19 20 ] Invariably, three to six doses of 0.–0.5 mL administered at intervals of 2‒3 weeks have been used with outcome as varied [ Table 4 ]. For instance, three doses of 0.5 mL injected once in 3 weeks for up to three doses resulted in complete clearance in only 87% of plantar warts patients, whereas 5 intralesional doses of 0.3 mL given once in 2 weeks lead to complete resolution in only 63% of 65 patients in two separate studies.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of intralesional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of common warts in adults

Chauhan¹,

Mahajan²,

Mehta³

et al. 2019

Indian Dermatol Online J

View full text Add to dashboard Cite

Measles, mumps and rubella vaccine as an intralesional immunotherapy in treatment of warts

Cited by 11 publications

References 15 publications

Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: A randomized controlled trial

Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: A randomized controlled trial

Effectiveness of measles, mumps and rubella vaccine as immunotherapeutic agent for cutaneous viral warts

The efficacy and safety of intralesional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of common warts in adults

Contact Info

Product

Resources

About